candidiasis

Newark, New Castle, USA, May 26, 2023 (GLOBE NEWSWIRE) -- Growth Plus Reports estimated the size of the global market for recurrent vulvovaginal candidiasis in 2022 to be worth US$ 1.02…

<!-- Name:DistributionId Value:8793824 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False -->…

An FDA advisory committee on Tuesday overwhelmingly recommended approval, with a "limited…

JERSEY CITY, N.J., June 23, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and…

New interim analysis of the Phase 3 CARES study showed complete or partial response in 78% of the 18 patients treated with ibrexafungerp for infections caused by Candida auris, a…

The oral selective JAK-1 inhibitor upadacitinib (Rinvoq) showed efficacy through 1 year among…